华兰疫苗(301207) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥14,578,885.25, representing a 32.67% increase compared to ¥10,989,066.50 in the same period last year[5] - The net profit attributable to shareholders was -¥849,919.03, an improvement of 79.39% from -¥4,124,253.29 year-over-year[5] - The company reported a basic earnings per share of -¥0.0023, improving by 80.00% from -¥0.0115 in the same period last year[5] - The weighted average return on equity was -0.02%, an improvement from -0.19% year-over-year[5] - The total profit (loss) for the period was -7,297,154.69, an improvement from -10,534,334.31 in the previous period, indicating a reduction in losses[35] - The net profit (loss) attributable to the parent company was -849,919.03, compared to -4,124,253.29 in the previous period, showing a significant decrease in losses[35] Cash Flow - The net cash flow from operating activities was -¥51,709,044.15, a decline of 121.25% compared to ¥243,311,535.68 in the previous year[5] - Cash inflows from operating activities totaled 271,671,609.62, down from 595,713,661.48 in the previous period, reflecting a decline in cash generation[38] - Cash outflows from operating activities amounted to 323,380,653.77, compared to 352,402,125.80 in the previous period, indicating a decrease in cash outflows[38] - The net cash flow from investing activities was -469,050,302.04, worsening from -279,933,599.29 in the previous period[41] - Cash inflows from financing activities reached 2,254,768,800.00, compared to 300,000,000.00 in the previous period, indicating a substantial increase in financing[41] - The net increase in cash and cash equivalents was 1,730,171,953.82, significantly higher than 260,860,019.70 in the previous period[41] Assets and Liabilities - Total assets increased by 49.14% to ¥6,746,296,460.98 from ¥4,523,446,917.50 at the end of the previous year[5] - Total liabilities decreased slightly to CNY 1,694,850,780.34 from CNY 1,715,354,421.76, a reduction of 1.1%[28] - The equity attributable to the parent company increased significantly to CNY 5,051,445,680.64 from CNY 2,808,092,495.74, representing an increase of 79.3%[28] Shareholder Information - The total number of common shareholders at the end of the reporting period is 34,703, with the top ten shareholders holding 67.50% of the shares[12] - The top shareholder, Hualan Biological Engineering Co., Ltd., holds 270 million shares, representing 67.50% of the total shares[12] - The company has a total of 36 million shares held by Cyber Creator Limited, accounting for 9.00% of the shares[12] - The company has a total of 270 million shares under lock-up conditions, which are set to be released on August 18, 2025[16] Operational Highlights - The company raised ¥2,250,931,300.01 from financing activities, a significant increase of 656.66% compared to ¥297,482,083.31 in the previous year[7] - The company experienced a 75.18% decrease in operating costs, amounting to ¥234,777.35, attributed to vaccine returns and increased costs from a wholly-owned subsidiary[7] - The company reported a 77.56% increase in investment income, reaching ¥4,325,579.33, due to higher financial management returns[11] - Research and development expenses increased to CNY 35,308,146.72, up from CNY 31,389,740.69, indicating a growth of 12.3%[32] - The company plans to continue expanding its market presence and investing in new product development[30] - Future guidance indicates a focus on enhancing operational efficiency and exploring potential mergers and acquisitions[30] Inventory and Receivables - Inventory increased by 209.19% to ¥332,096,723.22, primarily due to an increase in raw materials and work-in-progress[7] - The company reported accounts receivable of approximately 1.206 billion RMB, down from 1.439 billion RMB at the beginning of the year[21] - The company has 1.029 billion RMB in trading financial assets, an increase from 825.82 million RMB at the beginning of the year[21] - The company's inventory increased to approximately 332.10 million RMB from 107.41 million RMB at the beginning of the year[21] Market Activity - The company has successfully registered a quadrivalent influenza virus split vaccine for children in February 2022[20]